Angiotensin II Activates I KappaB Kinase Phosphorylation of RelA at Ser 536 to Promote Myofibroblast Survival and Liver Fibrosis
Overview
Authors
Affiliations
Background & Aims: The transcription factor nuclear factor-kappaB (NF)-kappaB promotes survival of hepatic myofibroblasts and fibrogenesis through poorly defined mechanisms. We investigated the activities of angiotensin II and I kappaB kinase (IKK) in regulation of NF-kappaB activity and the role of these proteins in liver fibrosis in rodents and humans.
Methods: Phosphorylation of the NF-kappaB subunit RelA at serine 536 (P-Ser(536)-RelA) was detected by immunoblot and immunohistochemical analyses. P-Ser(536)-RelA function was assessed using vectors that expressed mutant forms of RelA, cell-permeable blocking peptides, and assays for RelA nuclear transport and apoptosis. Levels of P-Ser(536)-RelA were compared with degree of fibrosis in liver sections from chronically injured rats and patients with hepatitis C virus-mediated fibrosis who had been treated with the AT1 antagonist losartan.
Results: Constitutive P-Ser(536)-RelA is a feature of human hepatic myofibroblasts, both in vitro and in situ in diseased livers. Autocrine angiotensin II stimulated IKK-mediated phosphorylation of RelA at Ser(536), which was required for nuclear transport and transcriptional activity of NF-kappaB. Inhibition of angiotensin II, the angiotensin II receptor type 1 (AT1), or IKK blocked Ser(536) phosphorylation and stimulated myofibroblast apoptosis. Treatment of fibrotic rodent liver with the angiotensin converting enzyme (ACE) inhibitor captopril or the IKK inhibitor sulphasalazine resulted in loss of P-Ser(536)-RelA-positive myofibroblasts and fibrosis regression. In human liver samples, increased numbers of P-Ser(536)-RelA-positive cells were associated with fibrosis that regressed following exposure to losartan.
Conclusions: An autocrine pathway that includes angiotensin II, IKK, and P-Ser(536)-RelA regulates myofibroblast survival and can be targeted to stimulate therapeutic regression of liver fibrosis.
Zhang X, Wang S, Liang L, Hu F, Zhang X, Cui X J Mol Histol. 2025; 56(2):91.
PMID: 39961876 DOI: 10.1007/s10735-025-10364-z.
He Y, Jiang J, Ou L, Chen Y, Abudukeremu A, Chen G Cell Death Discov. 2025; 11(1):49.
PMID: 39910053 PMC: 11799324. DOI: 10.1038/s41420-025-02312-3.
He Y, Ou L, Jiang J, Chen Y, Abudukeremu A, Xue Y World J Gastroenterol. 2025; 31(4):93179.
PMID: 39877717 PMC: 11718647. DOI: 10.3748/wjg.v31.i4.93179.
Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D J Clin Med. 2025; 14(2).
PMID: 39860434 PMC: 11765821. DOI: 10.3390/jcm14020428.
Duan H, Gong M, Yuan G, Wang Z J Clin Exp Hepatol. 2024; 15(2):102459.
PMID: 39722783 PMC: 11667709. DOI: 10.1016/j.jceh.2024.102459.